|Brief Description||Principal Investigator|
To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
||White, Richard Laverne|
|To compare invasive disease-free survival for the combination of at least 5 years endocrine therapy and 2- year palbociclib treatment vs 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer.||Vallabhaneni, Geetha|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|The purpose of this study is to evaluate the objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic tumors.||Amin, Asim|
|Celgene ABI-007-ST-001||Carrizosa, Daniel Ricardo|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
Primary: to compare radioactive seed localization (RSL) and wire-guided localization (WL) based on negative margins in malignant disease where negative margins is defined as no tumor on ink in invasive disease, and greater than or equal to 2mm from the inked margin in non-invasive disease (DCIS).
Secondary: to compare RSL and WL base on the following: total procedure cost, subject satisfaction over time, time from subject consult to operating room, radiologist satisfaction, time in radiology, s
The primary objective of this study is to assess the safety and feasibility of combining anastrozole and palbociclib in the following two cohorts: Cohort A) as first-line therapy and Cohort B) as maintenance therapy after first-line chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer. This objective will be evaluated in terms of the rate of permanent treatment discontinuation of palbociclib due to neutropenia for each cohort and compare them to
|Tan, Antoinette Roslyn|
|TBD||Tan, Antoinette Roslyn|
|To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.||Vallabhaneni, Geetha|
|This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.||Sharp, Hadley Jean|
|The primary objective is to assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS).||Tan, Antoinette Roslyn|
|The primary safety objective for this study is to evaluate the safety and tolerability of the following combination treatments administered q3w to patients with HER2-positive MBC or operable LABC or inflammatory EBC: Atezolizumab in combination with trastuzumab and pertuzumab and Atezolizumab in combination with trastuzumab emtansine||Fisher, Julie Gottlieb|
|To evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Phase 2: Approximately 12 months ] [ Designated as||Tan, Antoinette Roslyn|